Prognosis
Adderall Shortages in US Spread to Two More Drug Suppliers
This article is for subscribers only.
Two more pharmaceutical companies are having difficulty supplying Adderall to US patients with attention-deficit/hyperactivity disorder as shortages plague the market.
Lannett Co. and Par Pharmaceuticals, part of Endo International Plc, are the latest companies with limited supply of some doses of generic extended-release Adderall, according to a website updated Monday by the University of Utah’s drug-information service, which tracks drug shortages.